WO1998025594A3 - Nouveau traitement - Google Patents

Nouveau traitement Download PDF

Info

Publication number
WO1998025594A3
WO1998025594A3 PCT/EP1997/006971 EP9706971W WO9825594A3 WO 1998025594 A3 WO1998025594 A3 WO 1998025594A3 EP 9706971 W EP9706971 W EP 9706971W WO 9825594 A3 WO9825594 A3 WO 9825594A3
Authority
WO
WIPO (PCT)
Prior art keywords
lamotrigine
migraine
prophylaxis
treatment
patient
Prior art date
Application number
PCT/EP1997/006971
Other languages
English (en)
Other versions
WO1998025594A2 (fr
Inventor
John Morris Evans
Andrew Parsons
Original Assignee
Smithkline Beecham Plc
John Morris Evans
Andrew Parsons
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, John Morris Evans, Andrew Parsons filed Critical Smithkline Beecham Plc
Priority to JP52623998A priority Critical patent/JP2001510461A/ja
Priority to CA002274858A priority patent/CA2274858A1/fr
Priority to EP97953793A priority patent/EP0948325A2/fr
Publication of WO1998025594A2 publication Critical patent/WO1998025594A2/fr
Publication of WO1998025594A3 publication Critical patent/WO1998025594A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Abstract

L'invention concerne un procédé de traitement ou de prévention de la migraine chez l'humain. Le procédé consiste à administrer à un patient souffrant de la migraine une quantité effective de lamotrigine ou un sel pharmaceutiquement acceptable dudit produit.
PCT/EP1997/006971 1996-12-12 1997-12-09 Nouveau traitement WO1998025594A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP52623998A JP2001510461A (ja) 1996-12-12 1997-12-09 偏頭痛の治療および予防におけるラモトリジン
CA002274858A CA2274858A1 (fr) 1996-12-12 1997-12-09 Nouveau traitement
EP97953793A EP0948325A2 (fr) 1996-12-12 1997-12-09 Nouveau traitement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9625795.1 1996-12-12
GBGB9625795.1A GB9625795D0 (en) 1996-12-12 1996-12-12 Novel treatment

Publications (2)

Publication Number Publication Date
WO1998025594A2 WO1998025594A2 (fr) 1998-06-18
WO1998025594A3 true WO1998025594A3 (fr) 1998-09-17

Family

ID=10804309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/006971 WO1998025594A2 (fr) 1996-12-12 1997-12-09 Nouveau traitement

Country Status (5)

Country Link
EP (1) EP0948325A2 (fr)
JP (1) JP2001510461A (fr)
CA (1) CA2274858A1 (fr)
GB (1) GB9625795D0 (fr)
WO (1) WO1998025594A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012741A1 (fr) * 2002-07-29 2004-02-12 Glaxo Group Limited Formulations a liberation prolongee contenant de la lamotrigine
EP1438956A1 (fr) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Dérivés alpha-aminoamides en tant qu'agents antimigraine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459829A1 (fr) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Composés pharmacologiques actifs sur le système nerveux central
EP0459830A1 (fr) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Composés CNS pharmacologiquement actifs
WO1993016700A1 (fr) * 1992-02-19 1993-09-02 The Wellcome Foundation Limited Utilisation de 3,5-diamino-6-(2,3-dichlorophenyle)-1,2,4-triazine pour traiter les douleurs et les oedemes
WO1994018972A2 (fr) * 1993-02-25 1994-09-01 Warner-Lambert Company Procedes permettant de traiter des maladies et troubles neurodegeneratifs avec des urees n-(2,6-aromatiques disubstitues)-n'-pyridinyle et d'autres composes anticonvulsivants
WO1997020827A1 (fr) * 1995-12-05 1997-06-12 Laboratorios Del Dr. Esteve, S.A. Derives de fluorophenyl-triazines et pyrimidines comme composes actifs sur le snc

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459829A1 (fr) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Composés pharmacologiques actifs sur le système nerveux central
EP0459830A1 (fr) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Composés CNS pharmacologiquement actifs
WO1993016700A1 (fr) * 1992-02-19 1993-09-02 The Wellcome Foundation Limited Utilisation de 3,5-diamino-6-(2,3-dichlorophenyle)-1,2,4-triazine pour traiter les douleurs et les oedemes
WO1994018972A2 (fr) * 1993-02-25 1994-09-01 Warner-Lambert Company Procedes permettant de traiter des maladies et troubles neurodegeneratifs avec des urees n-(2,6-aromatiques disubstitues)-n'-pyridinyle et d'autres composes anticonvulsivants
WO1997020827A1 (fr) * 1995-12-05 1997-06-12 Laboratorios Del Dr. Esteve, S.A. Derives de fluorophenyl-triazines et pyrimidines comme composes actifs sur le snc

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D'ANDREA ET AL.: "Effectiveness of lamotrigine in the prophylaxis of migraine with aura. An open pilot study", J. NEUROL. SCI., vol. 150, no. suppl, September 1997 (1997-09-01), pages s239, XP002065865 *
STEINER ET AL.: "Lamotrigine versus placebo in the prophylaxis of migraine with aura", CEPHALALGIA, vol. 17, no. 2, April 1997 (1997-04-01), pages 109 - 112, XP002065866 *
STEINER ET AL.: "Safety data from a placebo-controlled trial of lamotrigine", INT. CONGR. SYMP., SER.- R SOC. MED., vol. 214, 1996, pages 31 - 35, XP002065864 *

Also Published As

Publication number Publication date
CA2274858A1 (fr) 1998-06-18
WO1998025594A2 (fr) 1998-06-18
GB9625795D0 (en) 1997-01-29
EP0948325A2 (fr) 1999-10-13
JP2001510461A (ja) 2001-07-31

Similar Documents

Publication Publication Date Title
EP1555025A3 (fr) Utilisation d'analogues de déhydroépiandrostérone pour le traitement de l'asthme
AU6915396A (en) Multiple sclerosis treatment
CA2189658A1 (fr) Formes galeniques a liberation controlee de l'azithromycine
EP0831832A4 (fr) Procedes pour lutter contre des maladies infectieuses a l'aide de bis-benzimidazoles dicationiques
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
CA2130805A1 (fr) Utilisation de mannose-phosphates dans le traitement des fibroses
UA32429C2 (uk) Засіб для лікування нетримання сечі
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
CA2322878A1 (fr) Utilisation de selegiline ou de desmethylselegiline pour traiter les plaies, les brulures et les lesions cutanees
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
GB2277265B (en) Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema
WO1998025594A3 (fr) Nouveau traitement
WO2001042205A3 (fr) Traitement de maladies enteriques inflammatoires avec des composes de la vitamine d
WO1997026880A3 (fr) Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1
AU6502194A (en) Oestriol-containing hormonal agent for the prophylaxis and treatment of arterial conditions in humans, method of preparing it and its use
WO1994004159A3 (fr) Traitement du cancer a l'azt ou a l'aide d'agents d'alkylation ou de chelation
IL126158A0 (en) Method for treating substance abuse
CA2248753A1 (fr) Utilisation de l'olanzapine pour le traitement de l'agressivite excessive
MY118982A (en) Method of reducing tissue damage associated with ischemia
AU1554295A (en) Method for treatment and prevention of disease in animals
GB2318057A (en) Treatment of nocturnal polyuria using an ace inhibitor in combination with a diuretic
AUPM533894A0 (en) Prophylactic and therapeutic treatment of pathogenic infections in plants and animals
IT1285552B1 (it) Dispositivo e metodo per il trattamento di parti del corpo umano
AUPO372596A0 (en) Composition and method for the prevention and treatment of skin disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2274858

Country of ref document: CA

Ref country code: CA

Ref document number: 2274858

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1998 526239

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997953793

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09319845

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997953793

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997953793

Country of ref document: EP